Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 679 across all filing types
Latest filing 2025-11-20 Earnings Release
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update
Earnings Release Classification · 100% confidence The document is a press release titled 'GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update'. It provides a summary of financial highlights (cash position, revenue) and operational updates (pipeline progress) for the third quarter of 2025. This fits the definition of an Earnings Release (ER), as it is the initial announcement of quarterly financial results and key highlights, rather than a full quarterly report or a mere announcement of a report's publication. Q3 2025
2025-11-20 English
GENFIT : Information financière du troisième trimestre 2025 et point sur les activités de la Société
Earnings Release Classification · 100% confidence The document is a press release from GENFIT titled 'Information financière du troisième trimestre 2025 et point sur les activités de la Société'. It provides a summary of financial results (cash position, revenue) and operational updates for the third quarter of 2025. This fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results and key highlights, rather than a full interim report or a report publication announcement. 9M 2025
2025-11-20 French
GENFIT annonce la réalisation du retrait volontaire de ses « American Depositary Shares » du Nasdaq Stock Market
Delisting Announcement Classification · 100% confidence The document is a press release from GENFIT announcing the voluntary delisting of its American Depositary Shares (ADS) from the Nasdaq Stock Market and the filing of Form 15F with the SEC to suspend reporting obligations. This is a formal announcement regarding the removal of the company's stock from an exchange, which directly matches the definition of a Delisting Announcement (DLST).
2025-11-20 French
GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
Delisting Announcement Classification · 100% confidence The document is a press release announcing the voluntary delisting of the company's American Depositary Shares (ADSs) from the Nasdaq Stock Market. It explicitly states the effectiveness of the delisting and the filing of Form 15F with the SEC to suspend reporting obligations. This falls directly under the definition of a delisting announcement.
2025-11-20 English
GENFIT signe un partenariat de recherche avec EVerZom pour faire progresser une technologie de médecine régénérative basée sur les exosomes dans l’ACLF
Regulatory Filings Classification · 100% confidence The document is a press release announcing a new research partnership between GENFIT and EVerZom regarding regenerative medicine for ACLF. It details the nature of the collaboration, the strategic goals, and provides background information on both companies. It does not constitute a formal financial report, audit, or regulatory filing, but rather a corporate announcement of a business development activity. Under the provided categories, this fits best as a general regulatory announcement or corporate news release, which falls under the RNS (Regulatory Filings) category.
2025-11-10 French
GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF
Regulatory Filings Classification · 100% confidence The document is a press release announcing a new research collaboration between GENFIT and EVerZom. It details the nature of the partnership, the drug candidate involved, and the strategic goals of the collaboration. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a simple report publication announcement. As it is a general corporate announcement regarding business development and research activities, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate news.
2025-11-10 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.